Concord Biotech Invests USD 1,500 in Stellon Biotech Inc. for 75% Ownership

Concord Biotech Limited has invested USD 1,500 in Stellon Biotech Inc., a Delaware-incorporated pharmaceutical company established in December 2024. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share, resulting in 75% ownership in Stellon Biotech Inc. The objective is to expand Concord Biotech's business operations in the USA and utilize Stellon Biotech Inc. to distribute and sell its products in the United States. Stellon Biotech Inc. is currently in its pre-revenue phase and was specifically created to support the marketing and commercialization of products developed by Concord Biotech Limited.